EverHint – Dip Bounce V2 (Reclaim) – Top 15 Signals for Jun 25, 2026
Excerpt: 15 signals (from 32 total). Healthcare leads (13). price range $11-$328. 1 with insider buying. 5 with insider selling.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
The mixed session across major indices reflects a cautious but not panicked market environment. The Nasdaq's modest decline of 0.47% alongside the Dow's slight gain of 0.14% suggests rotation out of growth-heavy tech names and into more defensive or value-oriented areas — a backdrop that can create the kind of intraday dislocation that dip-bounce strategies are designed to exploit. When large-cap growth leads lower while broader indices hold relatively flat, individual names can overshoot to the downside before reclaiming key levels, which is precisely the setup the dip_bounce_v2_reclaim strategy targets.
Volatility, as measured by the VIX at 19.06 with a 2.31% intraday rise, sits in a moderate zone — elevated enough to produce meaningful intraday price swings, but not so extreme as to make entries unpredictable or stop-outs erratic. This level of volatility tends to be a sweet spot for reclaim-style signals, as price action is dynamic enough to generate clean bounce setups without the whipsaw risk that comes with VIX readings above 25. Traders should remain attentive to position sizing, as even moderate volatility can amplify both gains and losses on intraday moves.
The concentration of signals in the Healthcare sector is notable given the current risk-off tilt in equities. Healthcare historically attracts capital during periods of uncertainty due to its defensive characteristics, and the sector rotation implied by today's index divergence supports this theme. With 32 total signals skewing toward a sector known for relative stability, the signal pool may offer higher-probability setups with tighter risk parameters — though the broader market's cautious tone warrants disciplined entry execution and close attention to broader index direction as a confirmation filter.
📊 Signals (15 of 32 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | BTI | British American Tobac... | Consumer Defensive | $62.48 | 0.33 | — | $135.4B |
| 2 | VTRS | Viatris Inc. | Healthcare | $16.07 | 0.31 | — | $18.7B |
| 3 | EWTX | Edgewise Therapeutics,... | Healthcare | $41.69 | 0.31 | -$1,457,126 | $4.5B |
| 4 | AKO-B | Embotelladora Andina S.A. | Consumer Defensive | $29.43 | 0.25 | — | $4.6B |
| 5 | AVT | Avnet, Inc. | Technology | $90.81 | 0.25 | — | $7.4B |
| 6 | SLS | SELLAS Life Sciences G... | Healthcare | $10.53 | 0.24 | — | $1.5B |
| 7 | PRAX | Praxis Precision Medic... | Healthcare | $327.86 | 0.21 | — | $6.9B |
| 8 | MRK | Merck & Co., Inc. | Healthcare | $125.45 | 0.20 | — | $309.8B |
| 9 | AHR | American Healthcare RE... | Real Estate | $50.92 | 0.19 | — | $10.5B |
| 10 | SBRA | Sabra Health Care REIT... | Real Estate | $19.31 | 0.18 | — | $4.9B |
| 11 | TYRA | Tyra Biosciences, Inc. | Healthcare | $30.94 | 0.18 | — | $1.8B |
| 12 | CTRE | CareTrust REIT, Inc. | Real Estate | $39.80 | 0.18 | — | $9.4B |
| 13 | SLDE | Slide Insurance Holdin... | Financial Services | $18.06 | 0.18 | -$209,063 | $2.1B |
| 14 | OHI | Omega Healthcare Inves... | Real Estate | $47.62 | 0.17 | — | $14.2B |
| 15 | SION | Sionna Therapeutics, Inc. | Healthcare | $42.77 | 0.16 | -$5,732,084 | $1.9B |
Field Notes
Sector concentration: Healthcare (13), Real Estate (9), Technology (3)
Insider selling: SION (Sionna Therapeutics, Inc., -$5,732,084), EWTX (Edgewise Therapeutics, Inc., -$1,457,126), SLDE (Slide Insurance Holdings, Inc. Common Stock, -$209,063)
Data coverage: 28.1% insider, 0.0% congressional, 0.0% earnings, 12.5% news
Peer Analysis
SION (Sionna Therapeutics, Inc.): Leads 5 peers: JANX ($14.58), ABCL ($6.66), MAZE ($27.02), BHVN ($15.34), CLDX ($34.09)
SBRA (Sabra Health Care REIT, Inc.): Leads 5 peers: NHI ($76.42), ABR ($5.12), PECO ($42.21), EPR ($59.04), MAC ($25.48)
Recent Headlines
AVT (Avnet, Inc.)
- 4 Value Stocks to Buy as Lower Energy Costs Strengthen Market Outlook
MRK (Merck & Co., Inc.)
- The Big 3: Jpm, Dhr, Mrk
- MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
- European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
- Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets
- Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
PRAX (Praxis Precision Medicines, Inc.)
- Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results
- Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (13 signals) suggests sector-specific rotation. 1 signal with insider buying adds conviction. 5 signals showing insider selling warrant caution.
Trading tips for this strategy:
- Entry timing: Consider entering on next-day weakness or at previous day's close level
- Position sizing: Start small (1-2% of portfolio per signal)
- Stop loss: Below today's low (tight stops for mean reversion)
- Take profit: 3-5% bounce target, or previous day's high
- Time stop: Exit if no bounce in 1-3 days
Risk warning: Mean reversion can fail in strong downtrends - check broader market context
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.